<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04600323</url>
  </required_header>
  <id_info>
    <org_study_id>20-1672</org_study_id>
    <nct_id>NCT04600323</nct_id>
  </id_info>
  <brief_title>Bicarbonate Administration and Cognitive Function in Midlife and Older Adults With CKD</brief_title>
  <official_title>Bicarbonate Administration and Cognitive Function in Midlife and Older Adults With CKD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot, randomized, double-blinded, placebo-controlled, 12-month trial of 50&#xD;
      patients with CKD stage 3b-4 with metabolic acidosis to examine the effect of sodium&#xD;
      bicarbonate therapy on cognitive and cerebrovascular function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cognitive Function at 12 months</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Cognitive function will be determined using the NIH Toolbox-Cognition Battery computerized tests. Five major cognitive subdomains will be assessed including: 1)attention, 2)episodic memory, 3) working memory, 4) language, 5) executive function and 6)processing speed. The following summary scores will be recorded: Cognitive function composite score, Fluid cognition composite score and crystallized cognition composite score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cognitive Function composite score at 12 months</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>NIH Toolbox will be used to assess cognitive function composite score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Fluid Cognition Composite Score at 12 months</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>NIH Toolbox will be used to assess fluid cognition composite score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Crystallized cognition composite score at 12 months</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>NIH Toolbox will be used to assess crystallized cognition score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Cerebrovascular hemodynamics at 12 months</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Cerebrovascular reactivity will be measured using Transcranial Doppler US by assessing the change in mean blood flow velocity of the middle cerebral artery in response to a vasodilatory hypercapnia challenge. Cerebrovascular pulstatility index and resistance will be determined using the Gosling Pulsatility index.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Metabolic Acidosis</condition>
  <condition>Chronic Kidney Disease</condition>
  <condition>Cognitive Dysfunction</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo medication will be used at a dose of 0.5 mEq/kg-lean body weight/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium bicarbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium bicarbonate will be used at a dose of 0.5 mEq/kg-lean body weight/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Bicarbonate Tablets</intervention_name>
    <description>Participants will be given sodium bicarbonate at 0.5 mEq/kg-LBW/day for 12 months</description>
    <arm_group_label>Sodium bicarbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will be given placebo at 0.5 mEq/kg-LBW/day for 12 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 50-75 years old&#xD;
&#xD;
          -  Serum bicarbonate 16-22 mEq/L on 2 separate measurements (at least 1 day apart)&#xD;
&#xD;
          -  CKD stage 3b or 4 at time of screening (eGFR 15-44 ml/min/1.73m2)&#xD;
&#xD;
          -  Blood pressure &lt;130/80 mm Hg prior to randomization&#xD;
&#xD;
          -  Use of angiotensin converting enzyme inhibitor or angiotensin receptor blocker&#xD;
&#xD;
          -  Stable anti-hypertensive regimen for at least one month prior to randomization&#xD;
&#xD;
          -  Montreal Cognitive Assessment Score &gt; 24&#xD;
&#xD;
          -  No history of stroke&#xD;
&#xD;
          -  No history of dementia&#xD;
&#xD;
          -  No history of neurologic disease&#xD;
&#xD;
          -  Able to provide consent&#xD;
&#xD;
        Exclusion Criteria:• Significant comorbid conditions that lead the investigator to conclude&#xD;
        that life expectancy is less than 1 year&#xD;
&#xD;
          -  Use of chronic daily oral alkali within the last 3 months (including sodium&#xD;
             bicarbonate, calcium carbonate or baking soda)&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Serum potassium &lt; 3.3 or ≥ 5.5 mEq/L at screening&#xD;
&#xD;
          -  New York Heart Association Class 3 or 4 heart failure symptoms, known EF ≤30%, or&#xD;
             hospital admission for heart failure within the past 3 months&#xD;
&#xD;
          -  Factors judged to limit adherence to interventions&#xD;
&#xD;
          -  Anticipated initiation of dialysis or kidney transplantation within 12 months&#xD;
&#xD;
          -  Current participation in another research study&#xD;
&#xD;
          -  Pregnancy or planning to become pregnant or currently breastfeeding&#xD;
&#xD;
          -  Chronic use of supplemental oxygen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jessica Kendrick, MD</last_name>
    <phone>3037244837</phone>
    <email>Jessica.Kendrick@cuanschutz.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Kendrick, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Acidosis</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>At the conclusion of the study, data, which has been stripped of all personal identification information and coded with a number, will be made available to qualified individuals within the scientific community who apply for data use. The results and outcomes of this study will be made generally available by publication and journal articles submitted to PubMed Central in compliance with NIH access guidelines.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

